| Name | Title | Contact Details |
|---|
We believe everyone deserves affordable and convenient healthcare. Our mission is to build better ways for people to find the right care at the best price. Our technology gives all Americans — regardless of income or insurance status — the knowledge, choice, and care they need to stay healthy. GoodRx supports all Americans with their healthcare challenges. Since 2011, we`ve helped Americans save over $35 billion on prescriptions via savings cards, our website, and the GoodRx app, which is one of the most downloaded medical apps on both the Google Play and Apple App Store. We`re a customer-first company. That means making sure all our products and features are built around you. This approach guides how we operate, make decisions across our businesses, and work on new ideas for our customers. In 2021, an estimated 46 million U.S. adults were not able to afford needed care. We`re working to narrow this access gap. We have saved Americans over $30 billion on their medications.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
Burgess Health Center is committed to improve the quality of life for the people and communities we serve by providing excellent healthcare and exceptional patient experiences.
Transitional Living and Community Support is a Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AxioMed was founded to advance the standard of care for patients with degenerative spine conditions by progressing spine technology beyond fusion and first-generation artificial discs. Led by an experienced surgeon team and utilizing patented viscoelastic polymer technology, AxioMed has developed the next generation of artificial discs.